In a report released today, Matthew Gillmor from Robert W. Baird maintained a Hold rating on Teladoc (NYSE: TDOC), with a price target of $50. The company’s shares closed yesterday at $51.90, close to its 52-week high of $52.60.
According to TipRanks.com, Gillmor is a 4-star analyst with an average return of 14.2% and a 63.3% success rate. Gillmor covers the Services sector, focusing on stocks such as Encompass Health Corporation, Evolent Health, and R1 RCM Inc.
Currently, the analyst consensus on Teladoc is Strong Buy and the average price target is $54.73, representing a 5.5% upside.
In a report released yesterday, Cantor Fitzgerald also reiterated a Hold rating on the stock with a $50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $52.60 and a one-year low of $27.30. Currently, Teladoc has an average volume of 919.1K.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teladoc, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002 by George Byron Brooks and is headquartered in Purchase, NY.
